Adaptive Biotechnologies vs ImCheck Therapeutics
Adaptive Biotechnologies vs ImCheck Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adaptive Biotechnologies is on 69/100 and ImCheck Therapeutics on 60/100.
Where each one leads
Adaptive Biotechnologies
- our overall score: 69/100 against 60/100
- agent readiness: 39/100 against 34/100
- domain rating: 61/100 against 37/100
- funding raised: $300M against $164M
ImCheck Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Adaptive Biotechnologies | ImCheck Therapeutics |
|---|---|---|
| What it is | Leveraging the adaptive immune system to diagnose and treat disease. | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. |
| Category | Biotech, HealthTech, Genomics, Drug Discovery | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | services | platform | Biotech |
| Founded | 2009 | 2015 |
| Headquarters | Seattle, United States | Marseille, France |
| Status | Active | Active |
Size, funding and growth
| Measure | Adaptive Biotechnologies | ImCheck Therapeutics |
|---|---|---|
| Employees | Not published | 47 |
| Total funding | $300M | $164M |
| Latest round | Series D | Not published |
| LinkedIn followers | Not published | 11,647 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Adaptive Biotechnologies | ImCheck Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 69/100 | 60/100 |
| Traction | Not published | 57/100 |
| Team | Not published | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | Not published | 22/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | F (34/100) |
| Domain ratingLink authority, 0-100 | 61/100 | 37/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Adaptive Biotechnologies | ImCheck Therapeutics |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | WordPress | Not detected |
| Frameworks | Jquery | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Tag Manager | Google Analytics 4 |
Adaptive Biotechnologies vs ImCheck Therapeutics: common questions
Which is better, Adaptive Biotechnologies or ImCheck Therapeutics?
On our 0-100 score Adaptive Biotechnologies rates higher (69/100 against 60/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Adaptive Biotechnologies and ImCheck Therapeutics compare on the numbers?
Adaptive Biotechnologies leads on our overall score (69/100 against 60/100), agent readiness (39/100 against 34/100), domain rating (61/100 against 37/100), funding raised ($300M against $164M).
Read the full Adaptive Biotechnologies review and pricing or the ImCheck Therapeutics review and pricing. You can also browse other Adaptive Biotechnologies alternatives we track.